# Health Catalyst (HCAT) — Analyst Forecast

HCAT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/hcat/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Hold | 1 | 4 | 0 | 5 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $1.50 | $1.77 | $2.00 | 3 |

Last price $1.80 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Aug 21, 2026 | Canaccord Genuity | Downgraded | Buy → Hold | $1.80 |
| Aug 13, 2026 | Wells Fargo | Maintained | Equal-Weight | $1.50 |
| Aug 11, 2026 | Citigroup | Maintained | Neutral | $2.00 |
| Jul 21, 2026 | Canaccord Genuity | Maintained | Buy | $3.00 |
| Jun 26, 2026 | Wells Fargo | Maintained | Equal-Weight | $1.75 |
| May 12, 2026 | Stephens & Co. | Maintained | Equal-Weight | $1.75 |
| May 11, 2026 | Cantor Fitzgerald |  | Neutral | — |
| Mar 18, 2026 | Wells Fargo | Downgraded | Overweight → Equal-Weight | $1.00 |
| Mar 13, 2026 | Cantor Fitzgerald | Maintained | Neutral | $3.00 |
| Mar 13, 2026 | Stifel | Maintained | Hold | $2.00 |
| Mar 13, 2026 | Stephens & Co. | Maintained | Equal-Weight | $2.00 |
| Mar 13, 2026 | Canaccord Genuity | Maintained | Buy | $2.00 |
| Mar 13, 2026 | Citigroup | Maintained | Neutral | $1.75 |
| Jan 9, 2026 | Citigroup | Maintained | Neutral | $2.75 |
| Nov 11, 2025 | Wells Fargo | Maintained | Overweight | $5.00 |
| Nov 11, 2025 | Stifel | Maintained | Hold | $3.75 |
| Nov 11, 2025 | Citigroup | Maintained | Neutral | $3.25 |
| Oct 8, 2025 | Keybanc | Maintained | Overweight | $4.00 |
| Oct 8, 2025 | Evercore ISI Group | Maintained | In-Line | $3.00 |
| Oct 7, 2025 | Cantor Fitzgerald | Maintained | Neutral | $4.00 |

## Frequently Asked Questions

### What is the price target for HCAT stock?

The average 12-month analyst price target for Health Catalyst (HCAT) is $1.77, with a high estimate of $2.00 and a low of $1.50, across 3 analysts.

### Is HCAT a buy, sell, or hold?

Analysts covering Health Catalyst currently average a Hold rating: 1 buy, 4 hold and 0 sell, from 5 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for HCAT?

The average price target of $1.77 implies 1.85% downside from the last price of $1.80.

### What is the latest analyst rating on HCAT?

On Aug 21, 2026, Canaccord Genuity downgraded Health Catalyst to Hold with a price target of $1.80.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).